# US 5,858,981 A · Method of inhibiting phagocytosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,981 A
- Document ID: US5858981A
- Status: Granted
- Kind: A
- Application number: 08/657,884
- Filed: 1996-06-07
- Granted: 1999-01-12
- Earliest claimed: 1993-09-30
- Assignees: University of Pennsylvania
- Inventors: Alan D. Schreiber; Jong-Gu Park
- Web page: https://patentgrep.com/patent/US5858981A

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 38/07: Tetrapeptides
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/315: Phosphorothioates
- C12N 2310/53: partially self-complementary or closed
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.

## Claims

### Claim 1

A method of inhibiting the signal transduction of the .gamma. subunit of the IgE receptor Fc.epsilon.RI comprising introducing into lung cells of a mammal bearing said receptor a peptide inhibitor of Syk kinase, or a mimetic of said peptide, wherein said peptide comprises the sequence YXXL (SEQ ID NO:8), wherein XX represents any two amino acids,
said introduction being effected under conditions such that said signal transduction is inhibited.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said inhibitor is said peptide.

### Claim 3 (depends on 1)

The method according to claim 1 wherein XX represents the XX amino acids of a YXXL (SEQ ID NO:8) sequence of the cytoplasmic domain of the .gamma. chain of Fc.epsilon.RI.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said lung cells are mast cells.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said XX represents the XX amino acids of the YXXL sequence of the cytoplasmic domain of Fc.gamma.RIIA.

### Claim 6 (depends on 1)

The method according to claim 1 wherein said introduction is effected via aerosol administration to the lungs of a mammal.

### Claim 7

A method of inhibiting signal transduction of the .gamma. subunit of the IgE receptor Fc.epsilon.RI comprising introducing into cells of a mammal bearing said receptor an antisense construct that specifically binds Syk encoding sequences present in said cell under conditions such that said signal transduction is inhibited.

### Claim 8 (depends on 7)

The method of claim 7 wherein said cells are present in the lungs of an asthma patient.

### Claim 9 (depends on 8)

The method according to claim 8 wherein said introduction is effected by administering said construct to the lungs of said patient via aerosol or systemic administration.

### Claim 10 (depends on 1)

The method according to claim 1 wherein said inhibitor targets the interval region between the second SH2 domain and the catalytic (kinase) domain of Syk kinase.

### Claim 11

A method of inhibiting the release of a mediator from a Syk-producing cell of a mammal comprising introducing into said cell an antisense construct that specifically binds Syk encoding sequences present in said cell.

### Claim 12 (depends on 11)

The method according to claim 11 wherein said cell is present in a lung of an asthma patient.

### Claim 13 (depends on 7)

The method according to claim 7 wherein said cells are lung cells.

### Claim 14 (depends on 7)

The method according to claim 7 wherein said antisense construct is administered systemically to a mammal.

### Claim 15 (depends on 7)

The method according to claim 7 wherein said antisense construct is introduced into said cells in a liposome.

### Claim 16 (depends on 11)

The method according to claim 11 wherein said antisense construct is introduced into said cell in a liposome.

### Claim 17 (depends on 11)

The method according to claim 11 wherein said cell is a lung cell present in a mammal.

### Claim 18 (depends on 17)

The method according to claim 17 wherein said antisense construct is introduced into said cell via aerosol administration to the lungs of said mammal.

### Claim 19 (depends on 11)

The method according to claim 11 wherein said cell is a mast cell.

### Claim 20 (depends on 11)

The method according to claim 11 wherein said cell is a macrophage.

### Claim 21

A method of inhibiting the phagocytic potential of a mammalian cell expressing an Fc receptor comprising introducing into said cell a construct comprising, in the 5'-3' direction of transcription:
i) a promoter functional in said cell,
ii) a segment of double-stranded DNA, the transcribed strand of which comprises a sequence complementary to endogenous mRNA encoding Syk kinase, and
iii) a termination sequence functional in said cell,
wherein said construct is introduced under conditions such that said complementary strand is transcribed and binds to said endogenous mRNA thereby reducing expression of Syk kinase and inhibiting the phagocytic and signaling potential of said cell.

### Claim 22 (depends on 21)

The method according to claim 21 wherein said Fc receptor is Fc.gamma.RI, Fc.gamma.RIIA or Fc.gamma.RIIIA.

### Claim 23

A method of inhibiting the phagocytic potential of a mammalian cell expressing an Fc receptor comprising introducing into said cell a nucleic acid complementary to an endogenous mRNA encoding Syk kinase, wherein said nucleic acid is introduced under conditions such that said nucleic acid binds to said mRNA and thereby inhibits translation of said mRNA into Syk kinase.

### Claim 24 (depends on 23)

The method according to claim 23 wherein said Fc receptor is Fc.gamma.RI, Fc.gamma.RIIA or Fc.gamma.RIIIA.

### Claim 25 (depends on 21)

The method according to claim 21 wherein said sequence is complementary to a region of said endogenous mRNA free of secondary structure.

### Claim 26 (depends on 23)

The method according to claim 23 wherein said nucleic acid is complementary to a region of said mRNA free of secondary structure.

### Claim 27 (depends on 23)

The method according to claim 23 wherein said nucleic acid has a stem-loop structure.

### Claim 28 (depends on 23)

The method according to claim 23 wherein said nucleic acid has the sequence shown in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24.

### Claim 29

A method of inhibiting the phagocytic potential of a Syk-producing cell comprising introducing into said cell an antisense construct that specifically binds Syk encoding sequences present in said cell under conditions such that production of Syk is inhibited.
